Bruce Daniel Minsky

Bruce Daniel Minsky's AcademicInfluence.com Rankings

Bruce Daniel Minsky

Physics

#5111

World Rank

#6890

Historical Rank

Biophysics

#177

World Rank

#187

Historical Rank

physics Degrees

Bruce Daniel Minsky

Philosophy

#6047

World Rank

#9011

Historical Rank

Logic

#3237

World Rank

#4364

Historical Rank

philosophy Degrees

Download Badge

Physics
Philosophy

Bruce Daniel Minsky's Degrees

Doctorate Medicine University of California, San Francisco
PhD Biophysics University of California, Berkeley

Why Is Bruce Daniel Minsky Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Bruce Daniel Minsky's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. (2002) (1358)
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. (1998) (1301)
Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. (2005) (583)
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. (2007) (462)
Colorectal cancer (2010) (437)
Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. (2011) (432)
Male and female sexual and urinary function after total mesorectal excision with autonomic nerve preservation for carcinoma of the rectum. (1996) (406)
The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. (2005) (385)
Long-term Oncologic Outcome Following Preoperative Combined Modality Therapy and Total Mesorectal Excision of Locally Advanced Rectal Cancer (2005) (373)
Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. (2002) (350)
Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. (2003) (340)
Long-Term Results of Local Excision for Rectal Cancer (2002) (322)
Neuroendocrine Carcinomas of the Colon and Rectum (2004) (316)
Safety and efficacy of low anterior resection for rectal cancer: 681 consecutive cases from a specialty service. (1999) (301)
Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. (2005) (289)
Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. (2013) (288)
Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). (2009) (287)
Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. (1992) (266)
Long-Term Prognostic Significance of Extent of Rectal Cancer Response to Preoperative Radiation and Chemotherapy (2002) (264)
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. (2017) (260)
Rate of Pathologic Complete Response With Increased Interval Between Preoperative Combined Modality Therapy and Rectal Cancer Resection (2004) (252)
Rectus Flap Reconstruction Decreases Perineal Wound Complications After Pelvic Chemoradiation and Surgery: A Cohort Study (2005) (248)
The Development of a Validated Instrument to Evaluate Bowel Function After Sphincter-Preserving Surgery for Rectal Cancer (2005) (247)
Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer (1997) (246)
Variables correlated with the risk of lymph node metastasis in early rectal cancer (1992) (245)
Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†. (2015) (245)
Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. (2016) (239)
Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up. (1998) (232)
Adequacy of 1-cm Distal Margin After Restorative Rectal Cancer Resection With Sharp Mesorectal Excision and Preoperative Combined-Modality Therapy (2003) (222)
cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. (2008) (217)
Pathologic stage is most prognostic of disease‐free survival in locally advanced rectal cancer patients after preoperative chemoradiation (2008) (207)
Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. (1999) (206)
Sphincter Preservation in Low Rectal Cancer is Facilitated by Preoperative Chemoradiation and Intersphincteric Dissection (2009) (206)
Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach. (1992) (206)
Sphincter preservation with preoperative radiation therapy and coloanal anastomosis. (1995) (198)
Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. (2004) (197)
Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer. (1997) (191)
Patterns of Morphologic Alteration in Residual Rectal Carcinoma Following Preoperative Chemoradiation and Their Association With Long-term Outcome (2004) (179)
American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. (2007) (176)
Respiratory gating for liver tumors: Use in dose escalation (2003) (168)
Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. (2002) (167)
Surgical Salvage of Recurrent Rectal Cancer After Transanal Excision (2005) (167)
A Pathologic Complete Response of Rectal Cancer to Preoperative Combined-Modality Therapy Results in Improved Oncological Outcome Compared With Those Who Achieve No Downstaging on the Basis of Preoperative Endorectal Ultrasonography (2006) (166)
Long-term functional results of coloanal anastomosis for rectal cancer. (1994) (165)
Relationship of acute gastrointestinal toxicity and the volume of irradiated small bowel in patients receiving combined modality therapy for rectal cancer. (1995) (165)
Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography (2000) (164)
Colorectal Cancer Pelvic Recurrences: Determinants of Resectability (2004) (161)
T1 Adenocarcinoma of the Rectum: Transanal Excision or Radical Surgery? (2005) (161)
Resectable adenocarcinoma of the rectosigmoid and rectum. I. Patterns of failure and survival (1988) (160)
Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma. (2001) (159)
Hepatic resection: the last surgical frontier for colorectal cancer. (2005) (157)
Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results--Medicare. (2001) (155)
Adjuvant therapy for colorectal cancer. (1997) (153)
Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point. (2005) (152)
Gastric cancer. Clinical practice guidelines in oncology. (2006) (151)
Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care Study. (2000) (151)
2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. (2000) (145)
Surgical Salvage of Recurrent Rectal Carcinoma After Curative Resection: a 10-Year Experience (1999) (143)
Potentially curative surgery of colon cancer: patterns of failure and survival. (1988) (142)
Morphometric analysis of the translocation of lumenal membrane between cytoplasm and cell surface of transitional epithelial cells during the expansion-contraction cycles of mammalian urinary bladder (1978) (141)
Preoperative therapy for esophageal cancer: a randomized comparison of chemotherapy versus radiation therapy. (1990) (141)
All patients with small intramural rectal cancers are at risk for lymph node metastasis (1999) (138)
Selection criteria for local excision with or without adjuvant radiation therapy for rectal cancer (1989) (137)
Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. (1999) (137)
Resectable adenocarcinoma of the rectosigmoid and rectum. II. The influence of blood vessel invasion (1988) (137)
High dose rate intraoperative radiation therapy (HDR-IORT) as part of the management strategy for locally advanced primary and recurrent rectal cancer. (1998) (131)
A Prospective Pathologic Analysis Using Whole-Mount Sections of Rectal Cancer Following Preoperative Combined Modality Therapy: Implications for Sphincter Preservation (2007) (131)
Preoperative 5‐fluorouracil, low‐dose leucovorin, and concurrent radiation therapy for rectal cancer (1994) (130)
Factors Associated With Age Disparities Among Cancer Clinical Trial Participants. (2019) (125)
Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience (2016) (122)
Sacral Resection for Recurrent Rectal Cancer: Analysis of Morbidity and Treatment Results (2006) (121)
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. (2017) (121)
High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer. (2000) (121)
Predictors of Survival in Recurrent Rectal Cancer After Resection and Intraoperative Radiotherapy (2002) (121)
The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. (2011) (121)
Abdominoperineal resection for rectal cancer at a specialty center (2001) (113)
Preoperative radiation with or without chemotherapy and full-thickness transanal excision for selected T2 and T3 distal rectal cancers (2002) (113)
Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. (2008) (108)
T3N0 rectal cancer: Results following sharp mesorectal excision and no adjuvant therapy (1999) (107)
Oncologic Outcomes of Salvage Surgery for Epidermoid Carcinoma of the Anus Initially Managed With Combined Modality Therapy (2004) (105)
Lymphatic vessel invasion is an independent prognostic factor for survival in colorectal cancer. (1989) (105)
Stage I rectal cancer: identification of high-risk patients. (1998) (103)
The efficacy of preoperative 5‐fluorouracil, high‐dose leucovorin, and sequential radiation therapy for unresectable rectal cancer (1993) (102)
Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. (1990) (101)
Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. (2003) (100)
Neither FDG-PET Nor CT Can Distinguish Between a Pathological Complete Response and an Incomplete Response After Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Prospective Study (2013) (99)
Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience. (2008) (99)
The transformation of radiation oncology using real-time magnetic resonance guidance: A review. (2019) (97)
Colloid carcinoma of the colon and rectum (1987) (95)
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. (2017) (94)
Survival after radiotherapy in gastric cancer: systematic review and meta-analysis. (2009) (92)
The MRI-Linear Accelerator Consortium: Evidence-Based Clinical Introduction of an Innovation in Radiation Oncology Connecting Researchers, Methodology, Data Collection, Quality Assurance, and Technical Development (2016) (92)
Prognostic implications of the distribution of lymph node metastases in rectal cancer after neoadjuvant chemoradiotherapy. (2008) (91)
Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. (2018) (91)
Increased Endocrine Cells in Treated Rectal Adenocarcinomas: A Possible Reflection of Endocrine Differentiation in Tumor Cells Induced by Chemotherapy and Radiotherapy (2002) (91)
Significance of Acellular Mucin Pools in Rectal Carcinoma After Neoadjuvant Chemoradiotherapy (2011) (90)
Preoperative high‐dose leucovorin/5‐fluorouracil and radiation therapy for unresectable rectal cancer (1991) (90)
The national practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996-1999 Patterns of Care Study. (2003) (90)
Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. (2005) (89)
Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone. (2006) (86)
Respiratory gating for liver tumors: use in dose escalation. (2001) (86)
Squamous-Cell Carcinoma of the Rectum: A Rare but Curable Tumor (2007) (85)
Squamous-cell Carcinoma of the Anal Canal: Predictors of Treatment Outcome (2008) (83)
Colorectal cancer – Authors' reply (2010) (83)
An improved method for computerized tomography-planned transperineal 125iodine prostate implants. (1991) (81)
Residual Mesorectal Lymph Node Involvement Following Neoadjuvant Combined-Modality Therapy: Rationale for Radical Resection? (2004) (80)
A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients. (2003) (80)
An International Collaborative Standardizing a Comprehensive Patient-Centered Outcomes Measurement Set for Colorectal Cancer (2017) (79)
Functional and quality-of-life outcomes in patients with rectal cancer after combined modality therapy, intraoperative radiation therapy, and sphincter preservation (2000) (78)
Complications after preoperative combined modality therapy and radical resection of locally advanced rectal cancer: a 14-year experience from a specialty service. (2005) (78)
Potentially curative surgery of colon cancer: the influence of blood vessel invasion. (1988) (77)
A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. (2008) (77)
Phase I/II trial of pre-operative radiation therapy and coloanal anastomosis in distal invasive resectable rectal cancer. (1992) (76)
A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. (2002) (74)
Radiation therapy for medically inoperable stage I and II non-small cell lung cancer. (1989) (74)
Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy? (2017) (74)
Neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus: a preliminary analysis of the phase II intergroup trial 0122. (1996) (73)
Esophageal cancer. Clinical practice guidelines in oncology. (2006) (72)
Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning. (2008) (72)
Combined modality chemoradiation in elderly oesophageal cancer patients (2007) (71)
Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114). (2009) (70)
Conservative management of rectal cancer with local excision and postoperative adjuvant therapy. (1999) (69)
Local Excision and Postoperative Radiation Therapy for Rectal Cancer (1994) (69)
Molecular Biomarkers for the Evaluation of Colorectal Cancer (2017) (68)
Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer (2012) (67)
Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. (2004) (65)
Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. (2010) (64)
The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. (2008) (63)
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. (2007) (62)
Adjuvant therapy for rectal cancer--a good first step. (1997) (60)
Pre-operative combined 5-FU, low dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. (1993) (59)
Phospholipid profiles of human colon cancer using 31P magnetic resonance spectroscopy (1991) (59)
Aggressive surgical management of locally advanced primary and recurrent rectal cancer (1990) (59)
The multidisciplinary rectal cancer treatment: main convergences, controversial aspects and investigational areas which support the need for an European Consensus. (2005) (57)
Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). (2002) (57)
Phase I trial of preoperative cetuximab with concurrent continuous infusion 5-fluorouracil and pelvic radiation in patients with local-regionally advanced rectal cancer. (2006) (56)
International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer (2021) (55)
The evaluation and treatment of patients receiving radiation therapy for carcinoma of the esophagus (1999) (55)
Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial (2017) (54)
Multidisciplinary management of resectable rectal cancer. (1996) (54)
Short-course radiation versus long-course chemoradiation for rectal cancer: making progress. (2012) (53)
Prognostic significance of depth of gross or microscopic perirectal fat invasion in T3 N0 M0 rectal cancers following sharp mesorectal excision and no adjuvant therapy (2003) (53)
Evaluation of Preoperative and Postoperative Radiotherapy on Long-Term Functional Results of Straight Coloanal Anastomosis (2003) (52)
Radiation therapy for unresectable rectal cancer. (1991) (52)
The impact of radiation on functional outcomes in patients with rectal cancer and sphincter preservation. (2003) (50)
Adjuvant therapy of cancers of the colon and rectum. (2002) (50)
The clinical significance of vascular invasion in colorectal cancer (1989) (49)
Distal cT2N0 rectal cancer: is there an alternative to abdominoperineal resection? (2005) (49)
Radiation therapy facilities in the United States. (2006) (49)
Intraoperative parasympathetic nerve stimulation with tumescence monitoring during total mesorectal excision for rectal cancer. (2002) (48)
Characterization of malignant colon tumors with 31p nuclear magnetic resonance phospholipid and phosphatic metabolite profiles (1995) (47)
Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer (2015) (47)
Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. (2002) (47)
Sphincter preservation in rectal cancer by local excision and postoperative radiation therapy (1991) (46)
Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. (2019) (46)
Treatment of localized esophageal cancer. (2004) (46)
The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy (2020) (46)
30 Gy may be an adequate dose in patients with anal cancer treated with excisional biopsy followed by combined‐modality therapy (1999) (45)
Primary Adenocarcinoma of the Anus Treated With Combined Modality Therapy (2003) (44)
Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer. (2015) (44)
The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation (2016) (44)
The role of radiation therapy in the control of pain from pancreatic carcinoma. (1988) (42)
Can Differences in Bowel Function After Surgery for Rectal Cancer Be Identified by the European Organization for Research and Treatment of Cancer Quality of Life Instrument? (2007) (42)
Clinical validation of atlas-based auto-segmentation of pelvic volumes and normal tissue in rectal tumors using auto-segmentation computed system (2013) (42)
Esophageal cancer phospholipid characterization by 31P NMR (1993) (41)
Adjuvant therapy for rectal cancer – the transatlantic view (2003) (41)
Conservative management of rectal cancer with local excision and adjuvant therapy. (2001) (40)
Positron Emission Tomography Detection of Distant Metastatic or Synchronous Disease in Patients with Locally Advanced Rectal Cancer Receiving Preoperative Chemoradiation (2008) (40)
Outcome measures in multimodal rectal cancer trials. (2020) (39)
Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. (2017) (39)
Randomized, multicenter, phase IIb study of preoperative chemoradiotherapy in T3 mid-distal rectal cancer: raltitrexed + oxaliplatin + radiotherapy versus cisplatin + 5-fluorouracil + radiotherapy. (2008) (39)
Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality (2016) (39)
Combined modality therapy of extrahepatic biliary system cancer. (1990) (38)
Evaluation of 18F-FDG-PET for Early Detection of Suboptimal Response of Rectal Cancer to Preoperative Chemoradiotherapy: A Prospective Analysis (2011) (34)
Extrahepatic Biliary System Cancer: An Update of a Combined Modality Approach (1991) (34)
Imaging‐based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy (2018) (32)
Outcome Results of the 1996-1999 Patterns of Care Survey of the National Practice for Patients Receiving Radiation Therapy for Carcinoma of the Esophagus (2005) (32)
The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005. (2006) (31)
Sphincter preservation in rectal cancer. Preoperative radiation therapy followed by low anterior resection with coloanal anastomosis. (1998) (31)
Conservative management of anal leiomyosarcoma (1991) (31)
Prognostic Factors After Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus (2007) (31)
Laparoscopic Hyperthermic Intraperitoneal Chemotherapy is Safe for Patients with Peritoneal Metastases from Gastric Cancer and May Lead to Gastrectomy (2019) (31)
Treatment systems guidelines for primary rectal cancer from the 1996 Patterns of Care Study. (1998) (30)
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline Summary From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. (2017) (30)
Minimizing the toxicity of pelvic radiation therapy in rectal cancer. (1988) (30)
Clinical experience with local excision and postoperative radiation therapy for rectal cancer (1993) (28)
Longitudinal Quality-of-Life Analysis of RTOG 94-05 (Int 0123):A Phase III Trial of Definitive Chemoradiotherapy for Esophageal Cancer. (2011) (28)
Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. (2019) (28)
Preoperative combined modality treatment for rectal cancer. (1994) (28)
Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved (2018) (28)
A Phase II Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Gastric Cancer and Carcinomatosis or Positive Cytology (2020) (27)
Gastric Cancer Clinical Practice Guidelines. (2006) (27)
Outcome results of the 1996-1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagus. (2003) (27)
Esophageal Cancer Clinical Practice Guidelines. (2006) (27)
Patient acuity rating: quantifying clinical judgment regarding inpatient stability. (2011) (27)
Surgery and High-Dose-Rate Intraoperative Radiation Therapy for Recurrent Squamous-Cell Carcinoma of the Anal Canal (2011) (26)
Factors Associated with Local–Regional Failure After Definitive Chemoradiation for Locally Advanced Esophageal Cancer (2013) (26)
Predictive clinicopathologic factors for limited response of T3 rectal cancer to combined modality therapy (2008) (26)
Recursive partitioning analysis of pretreatment variables of 416 patients with locoregional esophageal cancer treated with definitive concomitant chemoradiotherapy on Intergroup and Radiation Therapy Oncology Group trials. (2004) (26)
Adjuvant radiation therapy for rectal cancer: is there finally an answer? (2001) (25)
Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease (2007) (25)
Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy (2019) (25)
Radiation therapy for rectosigmoid and rectal cancer: results of the 1992-1994 Patterns of Care process survey. (1998) (25)
NCCN practice guidelines for upper gastrointestinal carcinomas (1959) (24)
A phase I trial of preoperative radiation, proctectomy, and endoanal reconstruction. (1990) (24)
Expression of p27 in Residual Rectal Cancer after Preoperative Chemoradiation Predicts Long-term Outcome (2004) (24)
Squamous-cell Carcinoma of the Anal Canal: Predictors of Treatment Outcome (2008) (23)
New Strategies in Radiation Therapy: Exploiting the Full Potential of Protons (2013) (23)
Adjuvant therapy of resectable rectal cancer. (2002) (23)
Sucrase-isomaltase is an independent prognostic marker for colorectal carcinoma (1995) (23)
Phase I trial of postoperative 5-FU, radiation therapy, and high dose leucovorin for resectable rectal cancer. (1992) (23)
Mitigating the impact of COVID-19 on oncology: Clinical and operational lessons from a prospective radiation oncology cohort tested for COVID-19☆ (2020) (23)
The role of radiation therapy in gastric cancer. (1996) (23)
Intraoperative brachytherapy alone for incomplete resected recurrent rectal cancer. (1991) (23)
Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum (2012) (23)
Feasibility study of the treatment of primary unresectable carcinoma of the pancreas with 103Pd brachytherapy. (1996) (23)
Clinicopathologic impact of colloid in colorectal carcinoma (1990) (22)
Clinicopathologic features in rectal cancer treated by local excision and postoperative radiation therapy. (1995) (21)
Adjuvant therapy for rectal cancer (1999) (21)
Esophageal cancer phospholipids correlated with histopathologic findings: a 31P NMR study (1999) (20)
Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology (2017) (20)
Combined Modality Therapy for Rectal Cancer: The Relative Value of Posttreatment Versus Pretreatment CEA as a Prognostic Marker for Disease Recurrence (2012) (20)
Unique considerations in the patient with rectal cancer. (2011) (19)
Irinotecan, cisplatin, and radiation in esophageal cancer. (2002) (19)
Sphincter preservation in rectal sarcoma (1990) (19)
Counterpoint: long-course chemoradiation is preferable in the neoadjuvant treatment of rectal cancer. (2011) (19)
Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma. (2017) (18)
Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience (2019) (18)
Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials. (2020) (18)
Postoperative radiation therapy for rectal cancer combined with UFT/leucovorin. (2000) (18)
Adjuvant management of rectal cancer: the more we learn, the less we know. (2007) (18)
Patterns of care, tolerability and safety of the first cohort of patients treated on a novel high-field MR-Linac within the MOMENTUM Study: Initial results from a prospective Multi-Institutional Registry. (2021) (18)
Sphincter preservation for rectal cancer: fact or fiction? (2002) (18)
Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma (2018) (17)
Combined modality therapy in esophageal cancer: the Memorial experience. (2003) (17)
The ypT category does not impact overall survival in node negative gastric cancer (2018) (17)
Restorative or Preservative Operations in the Treatment of Rectal Cancer (1992) (17)
Yield of peritoneal cytology in staging patients with gastric and gastroesophageal cancer (2019) (17)
Ten-year results of preoperative radiation followed by sphincter preservation for rectal cancer: increased local failure rate in nonresponders. (2006) (17)
Efficacy of postoperative 5-FU, high-dose leucovorin, and sequential radiation therapy for clinically resectable rectal cancer. (1995) (17)
Chemotherapy and radiation of anal canal cancer: the first approach. (2004) (16)
Preoperative Chemoradiation Therapy Does Not Increase Risk of Anastomotic Leak in Patients With Gastric Cancer. (2017) (16)
Oxaliplatin-based combined-modality therapy for rectal cancer. (2003) (16)
A phase I trial of erlotinib, gemcitabine and radiation for patients with locally advanced, unresectable pancreatic cancer (2005) (16)
Proctectomy and coloanal reconstruction for rectal cancer (1990) (16)
Multidisciplinary case teams: an approach to the future management of advanced colorectal cancer. (1998) (16)
Radiation dose ≥54 Gy and CA 19–9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation (2012) (16)
Role of adjuvant therapy in adenocarcinoma of the rectum. (1999) (15)
Effect of a collagen substrate on the growth and development of normal and tumorigenic rat urothelial cells. (1983) (15)
Conservative treatment of rectal cancer with local excision and postoperative radiation therapy. (1995) (15)
Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era (2021) (15)
Imaging predictors of treatment outcomes in rectal cancer: An overview. (2018) (15)
Adjuvant therapy for rectal cancer: results and controversies. (1998) (15)
The treatment of hepatic metastases from colorectal cancer with radiation therapy alone or combined with chemotherapy or misonidazole. (1989) (15)
Sphincter preservation in rectal cancer (1999) (15)
A watch-and-wait approach to the management of rectal cancer. (2013) (15)
Carcinoma of the esophagus. Part 1: Primary therapy. (1999) (15)
High dose-rate intraluminal brachytherapy for carcinoma of the esophagus (1996) (15)
Linitis Plastica: a Distinct Type of Gastric Cancer (2019) (15)
The use of a prosthetic tissue expander to displace bowel from a brachytherapy implant site. (1990) (15)
Adjuvant radiation therapy for colon cancer. (1995) (14)
X-ray-mediated cross linking of protein and DNA. (1977) (14)
Radiation Therapy for Locally Advanced Esophageal Cancer. (2017) (14)
UFT® plus oral leucovorin calcium (Orzel™) and radiation in combined modality therapy: A comprehensive review (2001) (14)
Hyperfractionated Accelerated Reirradiation for Patients With Recurrent Anal Cancer Previously Treated With Definitive Chemoradiation (2016) (14)
Definitive hyperfractionated, accelerated proton reirradiation for patients with pelvic malignancies (2019) (14)
Repeat staging laparoscopy for gastric cancer after preoperative therapy (2018) (13)
65 Sphincter preservation with pre-operative radiation therapy (RT) and coloanal anastomosis: Long term follow-up (1997) (13)
31P NMR phospholipid characterization of intracranial tumors (1994) (13)
Automatic segmentation software in locally advanced rectal cancer: READY (REsearch program in Auto Delineation sYstem)-RECTAL 02: prospective study (2016) (13)
Progress in the treatment of locally advanced clinically resectable rectal cancer. (2011) (13)
Is preoperative chemoradiotherapy still the treatment of choice for rectal cancer? (2009) (13)
Conservative management of invasive rectal cancer: alternative to abdominoperineal resection. (1989) (13)
Meningioma phospholipid profiles measured by31P nuclear magnetic resonance spectroscopy (1994) (13)
Tumor regression grading in rectal cancer: is it time to move forward? (2014) (13)
Performance Status Restriction in Phase III Cancer Clinical Trials. (2020) (13)
Patterns of relapse in patients with localized gastric adenocarcinoma who had surgery with or without adjunctive therapy: costs and effectiveness of surveillance (2017) (13)
Extended perineal resection of distal rectal cancers: surgical advance, increased utilization of neoadjuvant therapies, proper patient selection or all of the above? (2008) (13)
Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy (2017) (13)
Colon Carcinoma Metastatic to the Trachea: Report of a Case and a Review of the Literature (1994) (12)
Patterns of care study decision tree and management guidelines for esophageal cancer. American College of Radiology. (1998) (12)
Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy (2018) (12)
Staging laparoscopy and peritoneal cytology in patients with early stage gastric adenocarcinoma (2020) (12)
Leiomyosarcoma of the anus treated with sphincter‐preserving surgery and radiation therapy (1986) (11)
Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial. (2020) (11)
Short-course radiation versus long-course chemoradiation for rectal cancer. (2012) (11)
Results After Rectal Cancer Resection With In-Continuity Partial Vaginectomy and Total Mesorectal Excision (2003) (11)
The role of adjuvant radiation therapy in the treatment of colorectal cancer. (1997) (11)
Association of Medicaid Insurance With Survival Among Patients With Small Cell Lung Cancer (2020) (11)
Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thrombus (2017) (11)
Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal (2017) (11)
Positron emission tomography during preoperative combined modality therapy for rectal cancer may predict ultimate pathologic response: A prospective analysis (2005) (11)
Sphincter preservation of leiomyosarcoma of the rectum and anus with local excision and brachytherapy (1999) (11)
NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience (2022) (10)
Carcinoma of the esophagus. Part 2: Adjuvant therapy. (1999) (10)
Multidisciplinary management of resectable rectal cancer. New developments and controversies. (2008) (10)
Phase II trial of preoperative combined modality therapy for esophageal carcinoma: Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy (2005) (10)
Phase I Trial of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) with Cisplatin, Mitomycin, and Paclitaxel in Patients with Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology (2020) (10)
Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer (2016) (10)
Association of Sex With Toxic Effects, Treatment Adherence, and Oncologic Outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trials of Rectal Cancer. (2019) (10)
Rectal cancer: Is 'watch and wait' a safe option for rectal cancer? (2013) (10)
The role of radiation therapy in rectal cancer. (1997) (9)
Management of locally advanced/unresectable rectal cancer (1995) (9)
Laparoscopic HIPEC for Low-Volume Peritoneal Metastasis in Gastric and Gastroesophageal Adenocarcinoma (2020) (9)
Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma (2017) (9)
Emerging trends in the treatment of rectal cancer (2019) (9)
101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy (2017) (9)
67 High dose rate intra-operative radiation therapy (HDR-IORT) for locally advanced/unresectable primary and locally recurrent rectal cancer (1997) (9)
Have the changes in treatment of rectal cancer made a significant difference to our patients? (2011) (9)
Ultrasound directed extrahepatic bile duct intraluminal brachytherapy. (1992) (9)
Primary combined-modality therapy for esophageal cancer. (2006) (9)
Results of local excision followed by postoperative radiation therapy for rectal cancer. (1997) (9)
Blood Vessel Invasion in Colorectal Cancer—an Alternative to TNM Staging? (1999) (9)
Assessment of setup uncertainty in hypofractionated liver radiation therapy with a breath-hold technique using automatic image registration–based image guidance (2019) (8)
Identifying the most predictive post-chemoradiation TRG system for rectal cancer. (2014) (8)
Adjuvant postoperative combined-modality therapy for rectal cancer. (1999) (8)
Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy: A Nomogram Associated with Long-Term Survivors (2016) (8)
Selection Criteria for Local Excision With or Without Radiation Therapy for Rectal Cancer Adjuvant (1989) (8)
Local excision and post-operative radiation therapy for rectal cancer (1993) (8)
Primary treatment of rectal cancer: present and future. (1999) (8)
PALLIATION OF ESOPHAGEAL CANCER: Palliative external beam radiation therapy and combined modality therapy (1996) (8)
Preoperative Chemoradiation versus Chemotherapy in Gastroesophageal Junction Adenocarcinoma. (2020) (8)
Tumor Regression Grade in Gastric Cancer After Preoperative Therapy (2020) (8)
Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer (2020) (8)
Prognostic Value of Lymph Node Yield After Neoadjuvant Chemoradiation for Gastric Cancer (2019) (8)
Hyperfractionated abdominal reirradiation for gastrointestinal malignancies (2018) (8)
The AJCC staging system does not predict survival in patients receiving multimodality therapy for esophageal cancer (2005) (7)
cT3N0 rectal cancer: Potential overtreatment with preoperative chemoradiation (CRT) is warranted. (2006) (7)
Combined Modality Therapy for Rectal Cancer (2010) (7)
IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer (2019) (7)
Current and future directions in adjuvant combined-modality therapy of rectal cancer. (1997) (7)
Potentially curable gastric adenocarcinoma treated without surgery. (2018) (7)
Phase II trial of preoperative cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy: PET scan after induction therapy may identify early treatment failure. (2006) (7)
Choosing the correct modality for the treatment of dysphagia in the patient with esophageal cancer. (2006) (7)
Sex-Based Disparities Among Cancer Clinical Trial Participants. (2019) (7)
Chemoradiation for rectal cancer: rationale, approaches, and controversies. (2010) (6)
38 Neoadjuvant chemotherapy plus concurrent chemotherapy and high dose radiation for squamous cell cancer of the esophagus — A preliminary analysis of intergroup trial 0122 (ECOG PE-289/RTOG 9012) (1995) (6)
Sphincter preservation in rectal cancer-continued evidence of success. (2000) (6)
Role of adjuvant therapy in rectal cancer (2002) (6)
Implementation and efficacy of a large-scale radiation oncology case-based peer-review quality program across a multinational cancer network. (2019) (6)
Conservative management of early rectal cancer. (1996) (6)
Course and predictors of postoperative outcomes in older patients with localized gastric adenocarcinoma treated preoperatively. (2016) (6)
Robotic lateral pelvic lymph node dissection after chemoradiation for rectal cancer: a Western perspective (2020) (6)
Management of resectable rectal cancer. American College of Radiology. ACR Appropriateness Criteria. (2000) (6)
Combined modality therapy for esophageal cancer. (2003) (6)
Dosimetry of aqueous 32P after soft-tissue infiltration following attempted intravenous administration. (1987) (6)
The verdict is in: the time for effective solutions to the global cancer burden is now. (2015) (6)
Quality of life after intensity-modulated radiation therapy for anal cancer (2015) (6)
Acute toxicity of neoadjuvant bolus 5-FU/methotrexate and leucovorin rescue followed by continuous infusion 5-FU plus pre-operative radiation therapy for rectal cancer (1996) (6)
Impact of body-mass index on treatment and outcome in locally advanced rectal cancer: A secondary, post-hoc analysis of the CAO/ARO/AIO-04 randomized phase III trial. (2021) (6)
Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-Institutional Analysis. (2021) (6)
Quality Research in Radiation Oncology analysis of clinical performance measures in the management of gastric cancer. (2013) (6)
Conservative management of rectal cancer with local excision and post-op radiation ± chemotherapy (1998) (6)
Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer (2020) (6)
Combined modality therapy of resectable rectal cancer: current approaches (2004) (6)
Dosimetric uncertainties resulting from interfractional anatomic variations for patients receiving pancreas stereotactic body radiation therapy and cone-beam CT image guidance. (2021) (6)
MR staging of anal cancer: what the radiologist needs to know (2019) (5)
Irinotecan in esophageal cancer. (2003) (5)
Combined-modality therapy of rectal cancer with irinotecan-based regimens. (2004) (5)
Navigating Nodal Metrics for Node-Positive Gastric Cancer in the United States: An NCDB-Based Study and Validation of AJCC Guidelines. (2021) (5)
Positron Emission Tomography Detection of Distant Metastatic or Synchronous Disease in Patients with Locally Advanced Rectal Cancer Receiving Preoperative Chemoradiation (2008) (5)
Clinically relevant study end points in rectal cancer. (2012) (5)
A birdcage resonator for intracavitary MR imaging. (1993) (5)
Tumor regression grade in gastric cancer after preoperative therapy. (2019) (4)
The national standards of practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996-1999 patterns of care study (2002) (4)
Relationship between initial management strategy and survival in patients with gastric outlet obstruction due to gastric cancer (2020) (4)
Preoperative Therapy Regimen Influences the Incidence and Implication of Nodal Downstaging in Patients with Gastric Cancer (2020) (4)
Preoperative therapy for rectal cancer: Short-course radiation vs. long-course chemoradiation (2014) (4)
Adjuvant external beam and intraoperative radiation therapy in rectal cancer. (1989) (4)
Concurrent lymphovascular and perineural invasion after preoperative therapy for gastric adenocarcinoma is associated with decreased survival (2021) (4)
Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation (2018) (4)
Patient-reported bowel and urinary function in long-term survivors of squamous cell carcinoma of the anus treated with definitive intensity-modulated radiotherapy and concurrent chemotherapy. (2022) (4)
Carcinoma of the esophagus (1998) (4)
A randomized phase II trial comparing two paclitaxel (P)-cisplatin (C) containing chemoradiation (CRT) regimens as adjuvant therapy in resected gastric cancer (RTOG Intergroup #0114) (2005) (4)
Benchmarks for nodal yield and ratio for node-positive gastric cancer. (2021) (4)
Seminars in colon & rectal surgery (2001) (4)
The Radiotherapy Quality Assurance Gap Among Phase III Cancer Clinical Trials. (2021) (3)
The national practice for patients receiving radiation therapy (RT) for carcinoma of the rectum (RC): Comparative analysis of outcome from the 1992–1994 and 1988–1989 patterns of care studies by academic (AC) vs. non-academic (NAC) centers (2004) (3)
Combined-modality therapy of rectal cancer with oxaliplatin-based regimens. (2004) (3)
Variations in Proton Therapy Coverage in the State of Texas: Defining Medical Necessity for a Safe and Effective Treatment. (2016) (3)
Professional Medical Writer Assistance in Oncology Clinical Trials (2020) (3)
Locally unresectable rectal cancer. American College of Radiology. ACR Appropriateness Criteria. (2000) (3)
Chemotherapy Versus Chemotherapy Plus Chemoradiation as Preoperative Therapy for Resectable Gastric Adenocarcinoma: A Propensity Score-Matched Analysis of a Large, Single-Institution Experience (2020) (3)
42 – Cancer of the Anal Canal (2010) (3)
Comparison of laparoscopy versus mini-laparotomy for jejunostomy placement in patients with gastric adenocarcinoma (2020) (3)
Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients with Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase I Trial and Imaging-based Biomarker Validation. (2022) (3)
Comparison of Locoregional versus Extended Locoregional Radiation Volumes for Patients with Nonmetastatic Gastro-esophageal Junction Carcinomas (2015) (3)
Radiation plus chemotherapy as adjuvant therapy for rectal cancer. (2002) (3)
Surgical resection and high dose rate intraoperative radiation therapy for locally recurrent rectal cancer. (2004) (3)
Microbiome Dynamics During Chemoradiotherapy for Anal Cancer. (2022) (3)
Impact factor and citation metrics in phase III cancer trials (2021) (3)
Cardiac toxicity of 5FU: Does prophylactic telemetry monitoring of patients at increased risk for cardiac toxicity improve safety? A 10-year experience. (2004) (3)
The use of capecitabine in the combined-modality therapy for rectal cancer. (2008) (3)
Radiation therapy in the treatment of esophageal cancer. (1994) (3)
Proton Therapy Outcomes for Localized, Unresectable Hepatocellular Carcinoma (2016) (3)
1032 Preliminary results of pre-operative 5-FU, low dose leucovorin (LV), and concurrent radiation therapy (RT) for resectable T3 rectal cancer (1996) (3)
Is Two-Dimensional Field Definition Sufficient for Pelvic Node Coverage in Rectal Cancer Compared to Technical Three-Dimensional Definition? (2013) (3)
57 High-dose rate intra-operative radiation therapy for local advanced and recurrent colorectal cancer (1996) (3)
Is the neutrophil-lymphocyte ratio (NLR) a predictive and prognostic factor in rectal cancer patients treated with neoadjuvant chemoradiation (nCRT)? (2016) (3)
A pathologic response score system after preoperative combined modality therapy as a predictor of metastases-free survival in the management of rectal carcinoma (2002) (2)
Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma (2021) (2)
Prognostic impact of lymphopenia and neutrophil-lymphocyte ratio for patients with anal squamous cell carcinoma. (2021) (2)
CEA as a blood-based biomarker in anal cancer (2021) (2)
One year follow-up reveals no difference in quality of life between high dose and conventional dose radiation: a quality of life assessment of RTOG 94-05 (2001) (2)
Paraneoplastic Thrombocytosis Is a Significant Independent Prognostic Factor for Overall and Progression Free Survival in Locally Advanced Pancreatic Cancer (2014) (2)
Rectal cancer: presentation with metastatic and locally advanced disease. American College of Radiology. ACR Appropriateness Criteria. (2000) (2)
Long-Term Patient-Reported Quality of Life and Functional Outcomes After Chemoradiation Using Intensity Modulated Radiotherapy for Anal Cancer. (2021) (2)
Phase I and II trial on infusional 5-fluorouracil and gefitinib in combination with preoperative radiotherapy in rectal cancer: 10-years median follow-up (2018) (2)
Patient-Reported GI Outcomes in Patients With Anal Cancer Receiving Modern Chemoradiation. (2020) (2)
Anal cancer. American College of Radiology. ACR Appropriateness Criteria. (2000) (2)
Adjuvant Chemotherapy for Stage III Colon Cancer (2017) (2)
Nurse Practitioner Navigation Program within a Rapid Access Bone Metastases Clinic Improves Patient Access to Radiation (2020) (2)
A Machine Learning Model Approach to Risk-Stratify Gastrointestinal (GI) Cancer Patients for Hospitalization and Mortality Outcomes. (2021) (2)
The role of radiation therapy in the treatment of esophagus cancer (2003) (2)
Gastrointestinal malignancies and supportive care trials: a snapshot of the last two decades (2020) (2)
Utility of endoscopic ultrasound-guided fine-needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma (2017) (2)
Combined modality therapy for rectal cancer. (2003) (2)
Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States (2022) (2)
HDR-IORT for Colorectal Cancer (1999) (2)
Low metabolic activity in primary gastric adenocarcinoma is associated with resistance to chemoradiation and the presence of signet ring cells (2020) (2)
Phase I trial of pre-operative combined radiation therapy, 5-FU, and low dose leucovorin for unresectable rectar cancer (1992) (2)
Prospective Phase 1/2 Clinical Trial: Evaluating Dose-Escalation for Esophageal Cancer (2015) (2)
The effect of IMRT on acute toxicity in patients with gastric cancer treated with preoperative chemoradiation. (2019) (2)
Short-Course Radiation As a Component of Definitive Multidisciplinary Treatment for Select Patients with Metastatic Rectal Adenocarcinoma (2017) (2)
Radiation Therapy Oncology Group. Research Plan 2002-2006. Gastrointestinal Cancer Committee. (2001) (1)
Patient acuity rating (2011) (1)
Microbiome Dynamics During Chemoradiotherapy for Anal Cancer (2021) (1)
Combined-modality Therapy for Rectal Cancer: Analysis of Potential Differences in Disease Presentation, Treatment Adherence, and Treatment Outcome According to Race (2014) (1)
Cancer of the rectum (1960) (1)
Stereotactic vs. Conventional Radiation Therapy in Patients With Pancreatic Cancer. (2021) (1)
Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials (2020) (1)
Clinical Associations of Treatment Failure After Radiation Therapy for Colorectal Liver Metastases (2020) (1)
MRI-based treatment decision making for rectal cancer. (2014) (1)
Future of therapy for rectal cancer. (2013) (1)
Neo-adjuvant Therapy (2001) (1)
Anal cancer treatment regimen considerations for the COVID-19 era: In regard to Tchelebi et al (2020) (1)
Patient Setup Management for Pancreatic SBRT: Daily CT Based Assessment of Setup Accuracy using Vertebral Bone, Fiducial Markers, Biliary Stent, and Soft-Tissue Targeting (2019) (1)
National practice for patients receiving radiation therapy for carcinoma of the rectum: comparative analysis of the 1992–1994 patterns of care study (2003) (1)
Quality Research in Radiation Oncology (QRRO): A Patterns of Care Analysis of Clinical Performance Measures in the Management of Gastric Cancer (GC) (2010) (1)
Lower gastrointestinal malignancies (1992) (1)
2039 Acute toxicity and efficacy of postoperative combined modality therapy for adenocarcinoma of the pancreas (1996) (1)
Present indications for adjuvant therapy in resectable rectal cancer. (2001) (1)
Utility of endoscopic ultrasound-guided fine-needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma. (2017) (1)
CHEMOTHERAPY AND RADIOTHERAPY AS PRIMARY TREATMENT OF ESOPHAGEAL CANCER (2008) (1)
Food and Drug Administration approvals in phase 3 Cancer clinical trials (2021) (1)
Staging of esophageal cancer in patients treated with initial chemoradiation: Findings of the patterns of care study (PCS) (2004) (1)
404 Lower gastrointestinal malignancies (1995) (1)
Does endoscopy accurately predict response to chemoradiation in patients undergoing esophagectomy? (2006) (1)
Ask The Experts: Unique management considerations for rectal cancer and colon cancer (2012) (1)
Patient-reported sexual function in long-term survivors of anal cancer treated with definitive intensity-modulated radiotherapy and concurrent chemotherapy. (2022) (1)
Combined-modality therapy for rectal cancer using irinotecan. (2002) (1)
Management of Locally Unresectable Rectal Cancer (2002) (1)
Pathologic Response and Postoperative Complications After Short-course Radiation Therapy and Chemotherapy for Patients With Rectal Adenocarcinoma. (2020) (1)
Sphincter preservation in rectal cancer. Introduction. (1998) (1)
Complications after preoperative combined modality therapy and radical resection of locally advanced rectal cancer : A 14-year experience from a specialty service. Authors' reply (2005) (1)
Gastrointestinal cancer committee (2001) (1)
Extent of gross or microscopic perirectal fat invasion does not predict outcome in T3N0 rectal cancers (1998) (1)
Treatment Patterns for Gastroesophageal Junction Adenocarcinoma in the United States † (2020) (1)
Neutrophil-Lymphocyte Ratio and Tumor Interface Response as Predictors of Outcomes for Prospective Cohort of Patients with Pancreatic Ductal Adenocarcinoma (2020) (1)
Radiation dose ≥54 Gy and CA 19–9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation (2012) (1)
A phase II trial of cytoreduction, gastrectomy, and hyperthermic intraperitoneal perfusion with chemotherapy for patients with gastric cancer and stage IV peritoneal disease. (2020) (1)
142 : A Randomized Phase II Study of Two Paclitaxel-Based Chemoradiotherapy Regimens for Patients With the Non–Operative Esophageal Carcinoma (RTOG 0113) (2006) (1)
Sociodemographic Factors Associated With Management of Gastric Cancer: QRRO/CURE Results (2012) (1)
Advances in the management of esophageal cancer (2015) (1)
Post-treatment CEA Values, and CEA Trends at the Time of Uncertain Post-treatment Imaging, Have Prognostic Value after Combined Modality Therapy for Rectal Cancer (2010) (1)
Recursive partitioning analysis (RPA) of pre-treatment variables for 416 patients with loco-regional esophageal cancer treated with concomitant chemoradiotherapy (CT-RT) on intergroup and radiation therapy oncology group (RTOG) trials (2002) (1)
CEA as a pharmacodynamic biomarker for metastatic anal cancer. (2018) (1)
Impact of endorectal filling on interobserver variability of MRI based rectal primary tumor delineation (2022) (1)
Dose-escalated pancreas radiotherapy for unresected pancreatic adenocarcinoma: Patterns of care and survival in the United States. (2023) (0)
Patient-Reported Bowel Function and Quality of Life Following Short and Long Course Radiotherapy for Locally Advanced Rectal Cancer (2022) (0)
Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution (2022) (0)
The Model of an ASTRO Servant Leader. (2021) (0)
Association of Radiotherapy Duration With Clinical Outcomes in Patients With Esophageal Cancer Treated in NRG Oncology Trials (2023) (0)
Outcomes with Proton and Photon Radiotherapy for Unresectable Hepatocellular Carcinoma (2020) (0)
Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of colorectal cancer (2012) (0)
Hyperfractionated Accelerated Reirradiation for Rectal Cancer: A Large Single-Institution Retrospective Analysis (2016) (0)
Rectus flap reconstruction decreases perineal wound complications following pelvic radiation and surgery: A cohort analysis (2004) (0)
Colorectal cancer Reply (2010) (0)
(P16) Hyperfractionated Abdominal Reirradiation for Gastrointestinal Malignancies (2018) (0)
Poster ViewingTargeting Multiple Liver Segments, Including the Entire Right Lobe, With Ablative Radiation Therapy as Salvage Therapy for Patients With Colorectal Liver Metastases Not Eligible for Two-Stage Hepatectomy (2017) (0)
How to Manage Complications of ADT (2018) (0)
Long-term survival in 101 metastatic gastroesophageal cancer (mGEAC) patients eventually treated with consolidative local therapy. (2017) (0)
Assessment of Emerging Technologies Used in Adjuvant Radiotherapy for Gastric Cancer: Preliminary Findings from the Quality Research in Radiation Oncology (QRRO) GI Committee Process Surveys (2010) (0)
Effect of Radiotherapy (RT) on Outcomes in Patients (Pts) With Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BRPC, LAPC). (2021) (0)
Progression-Free Survival is a Suboptimal Predictor for Overall Survival Among Metastatic Solid Tumor Clinical Trials (2020) (0)
Sponsor‐involved statistical analyses in Phase III cancer clinical trials (2020) (0)
Quality of Life After Intensity Modulated Radiation Therapy (IMRT) for Anal Cancer (2013) (0)
Patient-reported gastrointestinal outcomes in patients with anal cancer. (2020) (0)
Impact of Co-morbidities on Practice Patterns in the Management of Gastric Cancer: Findings from the Quality Research in Radiation Oncology (QRRO) GI Committee Process Survey (2011) (0)
Abstract P92: Provider Intuition Predicts Clinical Deterioration in Ward Patients (2008) (0)
100 High dose rate intraoperative brachytherapy for recurrent colorectal cancer (2000) (0)
Adjuvant Radiation Therapy in Potentially Curative Colorectal Neoplasia (1991) (0)
Outcomes and patterns of failures after hypofractionated radiation therapy for intrahepatic cholangiocarcinoma. (2019) (0)
Key Developments in Rectal Cancer Treatment (2007) (0)
Minimal residual local disease predicts improved survival after chemoradiotherapy in patients with squamous cell carcinoma of the esophagus (2007) (0)
Adjuvant postoperative radiation therapy for resectable rectal cancer. (1991) (0)
Candidate HPV-Specific T-Cells Expand in the Tumor Microenvironment During Chemoradiotherapy (2021) (0)
When should radiation be avoided in the treatment of rectal cancer (2018) (0)
Poster ViewingTime-Driven Activity-Based Costing (TDABC) in Radiation Oncology: A Method for Implementation (2017) (0)
Combined Modality Therapy for Rectal Cancer: Analysis of Potential Differences in Disease Presentation, Treatment Adherence, and Treatment Outcome According to Race (2010) (0)
41 – Cancer of the Rectum (2010) (0)
Impact of radiotherapy duration on outcomes in patients with esophageal cancer treated with definitive concurrent radiotherapy and chemotherapy on RTOG trials 8501 and 9405. (2015) (0)
Clinical assessment following preoperative combined modality therapy (CMT) for rectal carcinoma does not accurately predict pathologic response: A prospective analysis. (2004) (0)
Outcomes in older patients with localized gastric adenocarcinoma treated preoperatively. (2016) (0)
Correlation of pretreatment p63-positive subtype of gastroesophageal adenocarcinoma (GEAC) with pathologic complete response (pathCR) in patients receiving preoperative chemoradiation. (2016) (0)
Adjuvant treatment for rectal cancer: Short-course radiation vs. long-course chemoradiation (2013) (0)
Treatment of Pancreatic Cancer : Current Limitations , Future Possibilities (2017) (0)
An international multidisciplinary approach to the management of advanced colorectal cancer (First of two parts) (Reprinted from Eur J Surg Oncol, vol 23, Suppl A, August 1997) (1998) (0)
Combined-Modal i ty Therapy for Esophageal Cancer : High-Dose Versus Standard-Dose Radiat ion Therapy (2002) (0)
Treatment of unresectable/recurrent rectal cancer with external beam and/or intraoperative radiation techniques (2005) (0)
Outcomes Following Hyperfractionated Accelerated Reirradiation for Recurrent Anal Cancer (2016) (0)
Toxicity of pelvic radiation therapy (2001) (0)
Chapter 51 – Rectal Cancer (2016) (0)
1069 : A Randomized Phase II Trial Comparing Two Paclitaxel (P))-Cisplatin (C) Containing Chemoradiation (CRT) Regimens as Adjuvant Therapy in Resected Gastric Cancer (RTOG 0114) (2006) (0)
Clinical Impact of Positive Surgical Margins in Gastric Adenocarcinoma in the Era of Preoperative Therapy. (2023) (0)
Developing clinical indicators to effectively monitor a large network of radiation oncology practices. (2019) (0)
A prospective biomarker trial of microbiome, immune, and genomic markers as predictors of radiation response in anal squamous cell carcinoma. (2018) (0)
Mid and distal gastric cancers (1999) (0)
Patterns of radiotherapy practice in the management of gastric cancer: Preliminary findings from the Quality Research in Radiation Oncology (QRRO) GI Committee process surveys. (2011) (0)
Utility of Tumor Interface Stability as an Imaging Biomarker of Treatment Outcomes in Patients With Pancreatic Cancer Treated With Concurrent Bevacizumab and Radiation Therapy (2017) (0)
Potentially curable gastric adenocarcinoma (GAC) patients treated without surgery. (2018) (0)
Food and Drug Administration approvals in phase 3 Cancer clinical trials (2021) (0)
Preoperative chemoradiation does not affect long term bowel function of patients treated by low anterior resection with coloanal reconstruction (2000) (0)
Measuring cost in the value equation using time-driven activity-based costing (TDABC) at The University of Texas MD Anderson Cancer Center, Division of Radiation Oncology. (2017) (0)
PD01.20 Medicaid Outcome Inequalities in Small Cell Lung Cancer (2019) (0)
Toxicity of Radiotherapy for Rectal Cancer in Patients with Inflammatory Bowel Disease (2008) (0)
Perspective on...the new PSA screening recommendations. (2011) (0)
Plans for ISGIO's Fourth Annual GI Oncology Conference Under Way (2007) (0)
Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. (2021) (0)
Organ preservation in rectal cancer (1993) (0)
64 Radiation therapy for rectosigmoid and rectal cancer: Results of the 1996 patterns of care (PCS) process survey for patients treated in 1992–1994 (1997) (0)
Hyperfractionated abdominal reirradiation for gastrointestinal malignancies (2018) (0)
MO‐C‐BRB‐02: ASTRO President (2015) (0)
25. Radiation therapy for locally advanced esophageal cancer (2015) (0)
Radiation Therapy for High-Grade Neuroendocrine Carcinoma of the Rectum and Anal Canal (2014) (0)
OC-0419 Patterns of Care and Safety in 1800 patients treated on a high-field MR-Linac platform registry (2022) (0)
Patient-reported Bowel Function and Bowel-related Quality of Life After Pelvic Radiation for Rectal Adenocarcinoma: The Impact of Radiation Fractionation and Surgical Resection. (2023) (0)
Controversies in Preoperative Chemoradiation for Rectal Cancer (2009) (0)
Journal Watch: Our expert panel highlights the most important research articles across the spectrum of topics relevant to the field of colorectal cancer (2013) (0)
Patient-Reported Outcomes in Prospective Cohort of Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Undergoing Radiotherapy (2020) (0)
HPV-related anal cancer is associated with changes in the anorectal microbiome during cancer development (2023) (0)
Intracavitary birdcage resonator: Applications to the human prostate (1995) (0)
Postoperative adjuvant therapy for resectable rectal cancer (2001) (0)
146 The role of brachytherapy in carcinoma of the extrahepatic biliary system (1996) (0)
Assessment of setup uncertainty in hypofractionated liver radiation therapy with a breath-hold technique using automatic image registration–based image guidance (2019) (0)
Chapter 49 – Rectal Cancer (2012) (0)
Phase I trial of hyperthermic intraperitoneal chemoperfusion (HIPEC) with cisplatin, mitomycin, and paclitaxel in patients with gastric adenocarcinoma and carcinomatosis or positive cytology. (2019) (0)
Can IMRT Reduce Lymphopenia in Patients Treated with Preoperative Chemoradiation for Gastric Cancer? (2019) (0)
When should preoperative radiochemotherapy be performed (2018) (0)
CANCER of the colon. (1956) (0)
Review of Radiation Oncology Study Guide (2013) (0)
Radiotherapy for esophageal cancer (1994) (0)
The Czito/Bendell/Willett article reviewed (2006) (0)
The Move to Bundled Payments Will Be Paradigm-Changing (2012) (0)
Commentary (Minsky): Radiation Therapy for Resectable Colon Cancer (2006) (0)
Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer (2022) (0)
Risk of peritoneal carcinomatosis in localized gastric adenocarcinoma patients who undergo preoperative therapy and attempted surgery. (2017) (0)
Definitive liver radiotherapy for intrahepatic cholangiocarcinoma with extrahepatic metastases (2023) (0)
PH-0111 Impact of body-mass index on multimodal treatment and outcome in locally advanced rectal cancer (2021) (0)
Clinical outcomes following definitive treatment of young-onset, locally advanced rectal cancer: A single institution experience. (2021) (0)
Trial in Progress: 2019-1001 A Phase I Study of NBTXR3 Activated by Radiotherapy for Locally Advanced or Borderline Resectable Pancreatic Ductal Adenocarcinoma (LAPC or BRPC) (2022) (0)
Adjuvant chemotherapy (ACT) in stage III colon cancer: A study of 156,240 patients from 1985-2001. (2004) (0)
Radiation therapy for rectal cancer (2018) (0)
Neoadjuvant Treatment Strategies: Advanced Radiation Alternatives (2017) (0)
Whole B ody 18 FDG-PET a nd t he R esponse o f E sophageal Cancer t o I nduction T herapy: R esults o f a P rospective T rial (2003) (0)
Introduction (2022) (0)
Adjuvant therapy for colorectal cancer background and results of surgical resection (1997) (0)
Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis (2022) (0)
Radiation therapy alone or combined with chemotherapy in the treatment of esophageal cancer. (1996) (0)
New Paradigms in Rectal Cancer Multidisciplinary Care: Special Issue Introduction. (2022) (0)
Single Photon Emission Computed Tomography (SPECT) Functional Liver Imaging to Facilitate Reirradiation for Liver Malignancies: A Phase 1 Trial (2022) (0)
Intraoperative Radiation After Pelvic Short Course Radiation-Based Total Neoadjuvant Therapy for Patients With Rectal Adenocarcinoma at High Risk for Local Recurrence. (2022) (0)
Association of the anorectal microbiome and patient-reported gastrointestinal outcomes in patients with anal cancer. (2021) (0)
36 – Cancer of the Esophagus (2010) (0)
Radiationtherapyasasphincter-preserving techniqueindistaliuvasiverectalcan~r (1990) (0)
Postoperative Adjuvant Combined Modality Therapy (2001) (0)
29 A study of the treatment and management of advanced colorectal cancer (1996) (0)
Efficacy of three-drug induction chemotherapy followed by preoperative chemoradiation in patients with localized gastric adenocarcinoma (GAC). (2019) (0)
Is CA19-9 response following induction and consolidation therapy in locally advanced pancreatic cancer (LAPC) an early surrogate marker for eventual survival outcomes? (2015) (0)
Corrigendum to "Imaging predictors of treatment outcomes in rectal cancer: An overview" [Crit. Rev. Oncol./Hematol. 129, (September) (2018), 153-162]. (2019) (0)
Standardized approach to incident management across a radiation oncology network. (2018) (0)
Development and Validation of a Predictive Model for Toxicity of Neoadjuvant Chemoradiotherapy in Rectal Cancer in the CAO/ARO/AIO-04 Phase III Trial (2022) (0)
Differential Spatial Gene and Protein Expression Associated with Recurrence Following Chemoradiation for Localized Anal Squamous Cell Cancer (2023) (0)
Neoplasms of the Anus (2017) (0)
Determinants of Survival for Patients with Neoadjuvant-Treated Node-Negative Gastric Cancer (2021) (0)
Adjuvant combined modality therapy for rectal cancer. (1998) (0)
Comparison of Laparoscopy vs Mini-Laparotomy for Jejunostomy Placement in Patients with Gastric Adenocarcinoma (2019) (0)
Detecting the Dark Matter of Unpublished Clinical Cancer Studies: An Analysis of Phase 3 Randomized Controlled Trials. (2021) (0)
A Biology-Driven Radiomics Model for Unresectable Intrahepatic Cholangiocarcinoma Treated with Radiotherapy (2022) (0)
Association of Gut Microbiome Characteristics With the Late Gastrointestinal Toxicities After Pelvic Receiving Radiation Treatment for Cervical, Vaginal, and Anal Cancers. (2021) (0)
Who G ets A djuvant T reatment f or S tage I I a nd I II R ectal Cancer? I nsight F rom S urveillance, E pidemiology, a nd E nd Results-Medicare (2001) (0)
Radiation Dose ≥54 Gy is Associated with Improved Survival for Unresectable Pancreatic Cancer (2010) (0)
Radiation therapy as a sphincter-preserving technique in distal invasive rectal cancer. (1990) (0)
The role of brachytherapy in carcinoma of the extrahepatic biliary system (1993) (0)
Local Excision and Adjuvant Radiation Therapy for Carcinoma of the Rectum: National Patterns of Care (2005) (0)
217 – Characteristics and Survival of Gastric Cancer Patients with Pathological Complete Response (2019) (0)
IL-4 Adjuvant Therapy for Rectal Cancer (2006) (0)
Is CA19-9 Response Following Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer an Early Surrogate for Eventual Survival Outcomes? (2013) (0)
414 Lower gastrointestinal malignancies (1996) (0)
Clinical assessment following preoperative combined modality therapy (CMT) for rectal carcinoma does not accurately predict pathologic response: A prospective analysis (2004) (0)
Veterans Affairs Insurance Disparities for Metastatic Lung Cancer in the Hawaiian Islands (2020) (0)
Impact of pre-operative chemoradiotherapy on post-esophagectomy morbidity and mortality. (2006) (0)
412 Carcinoma of the esophagus (1997) (0)
2000 U pdate o f A merican S ociety o f C linical O ncology Colorectal C ancer S urveillance G uidelines (2000) (0)
418 Evolution of Outcomes of Patients With Pancreatic Ductal Adenocarcinoma Undergoing Pancreatoduodenectomy Following Preoperative Therapy (2016) (0)
Patient-Reported Outcomes After Chemoradiation in Patients With Anal Cancer: A Qualitative Analysis (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Bruce Daniel Minsky?

Bruce Daniel Minsky is affiliated with the following schools:

Emory University
MD Anderson Cancer Center
University of Chicago
University of Navarra
Cornell University
University of Massachusetts Medical School
Thomas Jefferson University

Bruce Daniel Minsky's Academic­Influence.com Rankings

Bruce Daniel Minsky's Degrees

Why Is Bruce Daniel Minsky Influential?

Bruce Daniel Minsky's Published Works

Published Works

What Schools Are Affiliated With Bruce Daniel Minsky?

Bruce Daniel Minsky's AcademicInfluence.com Rankings